Breakthrough treatment daraxonrasib demonstrates improved survival rates for patients with advanced disease
Patients across Kent battling advanced pancreatic cancer could soon have access to a promising new treatment following encouraging results from a major international clinical trial. The drug daraxonrasib has shown significant improvements in both overall survival and progression-free survival compared to standard chemotherapy for people with previously treated metastatic pancreatic ductal adenocarcinoma.
Breaking Down the Science
Pancreatic ductal adenocarcinoma represents the most common form of pancreatic cancer, accounting for about 95% of all cases. When the disease becomes metastatic, it means cancer cells have spread beyond the pancreas to other parts of the body, making treatment chiefly challenging.
The new drug works differently from traditional chemotherapy. Daraxonrasib is what scientists call a RAS(ON) inhibitor – a type of targeted therapy that blocks specific proteins that help cancer cells grow and survive. This approach aims to be more precise than conventional treatments, potentially causing fewer side effects even as improving outcomes.
Results from the phase 3 RASolute 302 trial were presented at a major cancer conference, showing that patients who received daraxonrasib lived longer and experienced delayed disease progression compared to those receiving standard chemotherapy alone. Phase 3 trials represent the final stage of testing before a drug can be considered for regulatory approval.
The Current Treatment Landscape
Pancreatic cancer remains one of the most challenging cancers to treat, with survival rates that haven’t improved heavily in recent decades. For patients whose disease has already been treated once and then progressed, options become increasingly limited.
Currently, patients in Kent receive pancreatic cancer care through specialist centres including Maidstone and Tunbridge Wells NHS Trust and East Kent Hospitals University NHS Foundation Trust. Treatment typically involves combinations of chemotherapy drugs, but responses are often short-lived and side effects can be significant.
The disease affects around 10,500 people each year across the UK, with symptoms often appearing late in the disease course. Many patients are diagnosed when the cancer has already spread, making treatments like the one studied in this trial above all relevant.
What Comes Next
Before daraxonrasib becomes available to patients here in Kent, it must go through regulatory approval processes. The Medicines and Healthcare products Regulatory Agency will need to review the full trial data to assess both the benefits and any potential risks.
If approved, the drug would then need to be evaluated by the National Institute for Health and Care Excellence, which determines whether new treatments offer good value for the NHS. This process typically takes several months to complete.
Cancer Research UK continues to fund research into pancreatic cancer treatments, recognising the urgent need for better options for patients facing this diagnosis.
Source: @NEJM
Key Takeaways
- New drug daraxonrasib showed improved survival in advanced pancreatic cancer trial
- Treatment targets specific proteins rather than using traditional chemotherapy approach
- Results represent progress for a cancer type with historically limited treatment options
What This Means for Kent Residents
While daraxonrasib isn’t yet available through the NHS, these results offer hope for local families affected by pancreatic cancer. Patients currently receiving treatment at Kent hospitals should discuss any questions about new therapies with their oncology teams, who can provide guidance on current options and potential future treatments. Anyone experiencing persistent abdominal pain, unexplained weight loss, or jaundice should contact their GP promptly, as early detection remains key for all pancreatic cancer treatments.